New Insights into the Heparan Sulfate Proteoglycan-binding Activity of Apolipoprotein E*

Defective binding of apolipoprotein E (apoE) to heparan sulfate proteoglycans (HSPGs) is associated with increased risk of atherosclerosis due to inefficient clearance of lipoprotein remnants by the liver. The interaction of apoE with HSPGs has also been implicated in the pathogenesis of Alzheimer's disease and may play a role in neuronal repair. To identify which residues in the heparin-binding site of apoE and which structural elements of heparan sulfate interact, we used a variety of approaches, including glycosaminoglycan specificity assays, 13C nuclear magnetic resonance, and heparin affinity chromatography. The formation of the high affinity complex required Arg-142, Lys-143, Arg-145, Lys-146, and Arg-147 from apoE and N- and 6-O-sulfo groups of the glucosamine units from the heparin fragment. As shown by molecular modeling, using a high affinity binding octasaccharide fragment of heparin, these findings are consistent with a binding mode in which five saccharide residues of fully sulfated heparan sulfate lie in a shallow groove of the α-helix that contains the HSPG-binding site (helix 4 of the four-helix bundle of the 22-kDa fragment). This groove is lined with residues Arg-136, Ser-139, His-140, Arg-142, Lys-143, Arg-145, Lys-146, and Arg-147. In the model, all of these residues make direct contact with either the 2-O-sulfo groups of the iduronic acid monosaccharides or the N- and 6-O-sulfo groups of the glucosamine sulfate monosaccharides. This model indicates that apoE has an HSPG-binding site highly complementary to heparan sulfate rich inN- and O-sulfo groups such as that found in the liver and the brain.

[1]  Gérard Siest,et al.  Heparin specifically inhibits binding of apolipoprotein E to amyloid β-peptide , 2000, Neuroscience Letters.

[2]  I. Fuki,et al.  Cell-surface heparan sulfate proteoglycans: dynamic molecules mediating ligand catabolism , 1997, Current opinion in lipidology.

[3]  R. Mahley,et al.  [13] Isolation and characterization of apolipoprotein E , 1986 .

[4]  E A Merritt,et al.  Raster3D: photorealistic molecular graphics. , 1997, Methods in enzymology.

[5]  H. Conrad Structures of Heparinoids , 1998 .

[6]  Sean Parkin,et al.  Novel mechanism for defective receptor binding of apolipoprotein E2 in type III hyperlipoproteinemia , 1996, Nature Structural Biology.

[7]  M C Phillips,et al.  A 13C NMR characterization of lysine residues in apolipoprotein B and their role in binding to the low density lipoprotein receptor. , 1988, The Journal of biological chemistry.

[8]  Yan Xu,et al.  Delayed catabolism of apoB-48 lipoproteins due to decreased heparan sulfate proteoglycan production in diabetic mice. , 2000, The Journal of clinical investigation.

[9]  R. Mahley,et al.  Apolipoprotein E: from atherosclerosis to Alzheimer's disease and beyond. , 1999, Current opinion in lipidology.

[10]  E. Masliah,et al.  LDL receptor‐related protein (LRP) in Alzheimer's disease: Towards a unified theory of pathogenesis , 2000, Microscopy research and technique.

[11]  M. Höök,et al.  Biosynthesis of heparin. Assay and properties of the microsomal N-acetyl-D-glucosaminyl N-deacetylase. , 1980, The Journal of biological chemistry.

[12]  K. Weisgraber Apolipoprotein E: structure-function relationships. , 1994, Advances in protein chemistry.

[13]  L. Kjellén,et al.  Reduced Sulfation of Liver Heparan Sulfate in Experimentally Diabetic Rats , 1983, Diabetes.

[14]  G. Siest,et al.  Kinetics of apolipoprotein E isoforms‐binding to the major glycosaminoglycans of the extracellular matrix , 1999, FEBS letters.

[15]  Suzanne Wehrli,et al.  Effects of Lipid Interaction on the Lysine Microenvironments in Apolipoprotein E* , 2000, The Journal of Biological Chemistry.

[16]  L. Andersson,et al.  Purification of antithrombin III by affinity chromatography , 1974 .

[17]  R. Mahley,et al.  Binding of arginine-rich (E) apoprotein after recombination with phospholipid vesicles to the low density lipoprotein receptors of fibroblasts. , 1979, The Journal of biological chemistry.

[18]  R. Mahley,et al.  Remnant lipoprotein metabolism: key pathways involving cell-surface heparan sulfate proteoglycans and apolipoprotein E. , 1999, Journal of lipid research.

[19]  R. Mahley,et al.  Apolipoprotein E: far more than a lipid transport protein. , 2000, Annual review of genomics and human genetics.

[20]  A. Oldberg,et al.  Cell-surface heparan sulfate. Mechanisms of proteoglycan-cell association. , 1980, The Journal of biological chemistry.

[21]  I. Goldberg,et al.  Oligosaccharide sequences of endothelial cell surface heparan sulfate proteoglycan with affinity for lipoprotein lipase. , 1994, The Journal of biological chemistry.

[22]  R. Mahley,et al.  Pathogenesis of type III hyperlipoproteinemia (dysbetalipoproteinemia). Questions, quandaries, and paradoxes. , 1999, Journal of lipid research.

[23]  R. Williams,et al.  Williams Textbook of endocrinology , 1985 .

[24]  R. Mahley,et al.  Variable heparan sulfate proteoglycan binding of apolipoprotein E variants may modulate the expression of type III hyperlipoproteinemia. , 1994, The Journal of biological chemistry.

[25]  R. Mahley,et al.  The receptor-binding domain of human apolipoprotein E. Binding of apolipoprotein E fragments. , 1983, The Journal of biological chemistry.

[26]  P. Kraulis A program to produce both detailed and schematic plots of protein structures , 1991 .

[27]  R. Mahley,et al.  Human apolipoprotein E. Determination of the heparin binding sites of apolipoprotein E3. , 1986, The Journal of biological chemistry.

[28]  F. Young Biochemistry , 1955, The Indian Medical Gazette.

[29]  H. Rauvala,et al.  Neurite Outgrowth in Brain Neurons Induced by Heparin-binding Growth-associated Molecule (HB-GAM) Depends on the Specific Interaction of HB-GAM with Heparan Sulfate at the Cell Surface (*) , 1996, The Journal of Biological Chemistry.

[30]  M. Saraste,et al.  FEBS Lett , 2000 .

[31]  M. Tremblay,et al.  Identification and characterization of a novel apolipoprotein E variant, apolipoprotein E3' (Arg136-->His): association with mild dyslipidemia and double pre-beta very low density lipoproteins. , 1995, Journal of lipid research.

[32]  U. Beisiegel,et al.  Apolipoprotein E isoforms and rare mutations: parallel reduction in binding to cells and to heparin reflects severity of associated type III hyperlipoproteinemia. , 1995, Journal of lipid research.

[33]  B. Rupp,et al.  Interaction of the N-terminal domain of apolipoprotein E4 with heparin. , 2001, Biochemistry.

[34]  K. Weisgraber,et al.  The functional characteristics of a human apolipoprotein E variant (cysteine at residue 142) may explain its association with dominant expression of type III hyperlipoproteinemia. , 1992, The Journal of biological chemistry.

[35]  R. Mahley,et al.  Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. , 1988, Science.

[36]  R. Mahley,et al.  Stable Expression and Secretion of Apolipoproteins E3 and E4 in Mouse Neuroblastoma Cells Produces Differential Effects on Neurite Outgrowth (*) , 1995, The Journal of Biological Chemistry.

[37]  D. Agard,et al.  Human apolipoprotein E. Role of arginine 61 in mediating the lipoprotein preferences of the E3 and E4 isoforms. , 1994 .

[38]  M. Forster,et al.  N.m.r. and molecular-modelling studies of the solution conformation of heparin. , 1993, The Biochemical journal.

[39]  Wayne A. Hendrickson,et al.  Structure of a heparin-linked biologically active dimer of fibroblast growth factor , 1998, Nature.

[40]  R. Schutgens The metabolic and molecular bases of inherited disease, seventh edition—3-volume set Edited by Charles R. Scriver, Arthur L. Beaudet, William S. Sly, and David Valle. New York, McGraw-Hill, 1995, $285.84 (xxxvi + 4605 pages and 93-page index), ISBN 0-07909-826-6 , 1995, Trends in Endocrinology & Metabolism.

[41]  K. Yoshida,et al.  Heparan sulfate isomers in cerebral arteries of Japanese women with aging and with atherosclerosis--heparitinase and high-performance liquid chromatography determinations. , 1997, Atherosclerosis.

[42]  D. Holtzman,et al.  Low density lipoprotein receptor-related protein mediates apolipoprotein E-dependent neurite outgrowth in a central nervous system-derived neuronal cell line. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[43]  G. Orr The use of the 2-iminobiotin-avidin interaction for the selective retrieval of labeled plasma membrane components. , 1981, The Journal of biological chemistry.

[44]  D. Rees,et al.  Diversity does make a difference: fibroblast growth factor-heparin interactions. , 1998, Current opinion in structural biology.

[45]  G. Giménez-Gallego,et al.  Common Binding Sites for β-Amyloid Fibrils and Fibroblast Growth Factor-2 in Heparan Sulfate from Human Cerebral Cortex* , 1999, The Journal of Biological Chemistry.

[46]  R. Mahley,et al.  Site-specific mutagenesis of human apolipoprotein E. Receptor binding activity of variants with single amino acid substitutions. , 1988, The Journal of biological chemistry.

[47]  M. Lyon,et al.  Liver heparan sulfate structure. A novel molecular design. , 1994, The Journal of biological chemistry.

[48]  R. Mahley,et al.  The receptor-binding domain of human apolipoprotein E. Monoclonal antibody inhibition of binding. , 1983, The Journal of biological chemistry.

[49]  K. Weisgraber,et al.  Conformational Reorganization of the Four-helix Bundle of Human Apolipoprotein E in Binding to Phospholipid* , 2000, The Journal of Biological Chemistry.

[50]  O. H. Lowry,et al.  Protein measurement with the Folin phenol reagent. , 1951, The Journal of biological chemistry.

[51]  J. Hirsh,et al.  Heparin Binding Proteins Contribution to Heparin Rebound After Cardiopulmonary Bypass , 1993, Circulation.

[52]  K. Weisgraber,et al.  Functional characterization of apolipoprotein E isoforms overexpressed in Escherichia coli. , 1999, Protein expression and purification.

[53]  W. März,et al.  Apolipoprotein E2 (Arg136 --> Cys) mutation in the receptor binding domain of apoE is not associated with dominant type III hyperlipoproteinemia. , 1998, Journal of lipid research.

[54]  T. Mazzone,et al.  Cell Surface Proteoglycans Modulate Net Synthesis and Secretion of Macrophage Apolipoprotein E* , 1996, The Journal of Biological Chemistry.

[55]  R. Rosenberg The Molecular and Genetic Basis of Neurological Disease , 1997 .

[56]  M. Höök,et al.  Distribution of sulphate and iduronic acid residues in heparin and heparan sulphate. , 1974, The Biochemical journal.

[57]  D C Rees,et al.  Heparin Structure and Interactions with Basic Fibroblast Growth Factor , 1996, Science.

[58]  M. Salmivirta,et al.  Age-dependent Modulation of Heparan Sulfate Structure and Function* , 1998, The Journal of Biological Chemistry.

[59]  U. Lindahl,et al.  Domain Structure of Heparan Sulfates from Bovine Organs* , 1996, The Journal of Biological Chemistry.

[60]  I. Pettersson,et al.  Decreased activity of the heparan sulfate-modifying enzyme glucosaminyl N-deacetylase in hepatocytes from streptozotocin-diabetic rats. , 1991, The Journal of biological chemistry.